Mental Health Startup Funding 2025-2026

What are all the funding deals in the mental health market from July 2025 to June 2026?

The table below lists every disclosed equity round raised by pure-play mental health companies between July 2025 and June 2026. We count as “pure-play” mental health companies those focused on diagnosing, treating, or clinically managing mental and substance use disorders through licensed providers, facilities, medications, or clinically validated digital tools.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how clinical mental health fits inside the broader healthcare opportunity, we cover it in our Mental Health market report.

How active has fundraising been in the mental health market?

As of June 2026, fundraising in the mental health market has been active by deal count and large by disclosed dollars. Over the past 12 months, companies raised 24 qualifying equity rounds and $1.381B combined, equal to 2.0 deals per month.

The count signal is meaningful because every deal in the sample came from a different company. That means the mental health market was not just one or two companies refinancing repeatedly.

The dollar signal is less steady than the deal signal. Average monthly capital was $115.07M, but the median month raised only $37.59M, which confirms that funding momentum depends on a few large events.

May 2026 and June 2026 through June 8 produced no qualifying disclosed rounds in the dataset. That does not mean the mental health market stopped moving, but it does show why public-source trackers should be read with date cutoffs in mind.

If you’re interested in knowing more about the clinical companies behind this activity, check our market report covering mental health.

How concentrated has fundraising been in the mental health market?

As of June 2026, fundraising in the mental health market is highly concentrated at the top. Over the past 12 months, the largest deal captured 26.98% of total capital, the top 3 deals captured 54.13%, and the top 5 captured 70.79%.

MapLight Therapeutics alone raised $372.5M, which is more than the entire disclosed market excluding rounds above $50M. That makes the top-line market number very sensitive to one psychiatric drug-development round.

The top 10 deals captured 86.08% of total capital. The remaining 14 deals shared only 13.92%, so the long tail of companies was active but capital-light.

This concentration means the mental health market should not be interpreted from total dollars alone. A better reading asks which clinical modality, stage, and risk profile actually drove the largest checks.

How much of the mental health funding signal is driven by outliers?

As of June 2026, much of the funding signal in the mental health market is driven by outliers. Over the past 12 months, total capital was $1.381B, but capital excluding rounds above $50M was only $343.32M.

The market contained 7 rounds of $50M or more, equal to 29.17% of all qualifying deals. Those rounds included MapLight, Talkiatry, Syremis, Grow Therapy, Salma Health, Gilgamesh Pharma, and Radial.

Four deals were above $100M, or 16.67% of the dataset. Those rounds alone shaped much of the market narrative because they sit in psychiatry, psychiatric therapeutics, and scaled care infrastructure.

The outlier dependency is also visible in average versus median round size. The average was $57.53M, while the median was $25M, so the average should not be read as the normal company experience.

Is the mental health market broad with many targets, or narrow with few fundable companies?

As of June 2026, the mental health market is broad by category but narrow by scaled funding outcomes. Over the past 12 months, 24 unique companies raised qualifying rounds, but the majority of capital still went to a small set of large clinical platforms and therapeutic developers.

The deal count spans therapy providers, mental health clinics, psychiatric medication services, psychiatry platforms, clinical apps, and addiction treatment. That breadth shows the mental health market is not locked into one delivery model.

However, the capital split is much narrower. Psychiatric Medication Services and Psychiatry Care Platforms together captured 63.55% of total capital from only 7 deals.

That means the investable center is not simply “mental health access.” The stronger funding signal sits around scarce clinical capacity, psychiatric prescribing, serious mental illness, interventional care, and differentiated psychiatric science.

Is mental health mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the mental health market is neither purely early-stage nor purely late-stage. Over the past 12 months, Series A was the most common stage with 11 deals, but Series D+ rounds captured 53.05% of all capital from only 3 deals.

Early-stage rounds, defined as Seed and Series A, raised $497.15M, or 36.00% of disclosed capital. That is a real formation signal, but it is boosted by large Series A rounds in therapeutics and advanced clinic models.

Late-stage rounds, defined as Series B, Series C, Series D+, and Growth Equity, raised $858.67M, or 62.19% of disclosed capital. The market still reserves its largest checks for companies with scale, clinical infrastructure, or institutional-grade development programs.

Seed remained small in the mental health market. Five Seed rounds made up 20.83% of deals but only 2.42% of capital, which means new-company formation exists but is not where funding intensity sits.

If you want to learn more about where investors are placing early versus late-stage bets, check our report on the mental health market.

Which categories attract the most investor attention in mental health?

As of June 2026, Therapy Care Providers attracted the most investor attention by deal count in the mental health market. Over the past 12 months, the category produced 6 deals, equal to 25.00% of all qualifying rounds.

Therapy Care Providers included Cartwheel Care, Marble Health, Triplemoon, Grow Therapy, Amaha, and Tava Health. The category was broad, but its capital-share-to-deal-share ratio was only 0.72, which means frequency did not translate into premium pricing.

Mental Health Clinics and Clinical Mental Health Apps each produced 5 deals, or 20.83% of activity. These categories show investors are still testing new clinic models and clinical software layers.

Psychiatric Medication Services produced only 4 deals, but it raised $622.5M. That made it the leading category by capital, even though it was only third by deal count.

Which categories attract disproportionately large checks in the mental health market?

As of June 2026, Psychiatric Medication Services attracted the most disproportionately large checks in the mental health market. Over the past 12 months, it produced 16.67% of deals but 45.08% of total capital, giving it a capital-share-to-deal-share ratio of 2.70.

The category’s average deal size was $155.63M, far above every other category. MapLight, Syremis, Gilgamesh, and Amani show how psychiatric drug development can dominate a mental health funding dataset.

Psychiatry Care Platforms also attracted outsized checks. The category produced only 3 deals but raised $255M, led by Talkiatry’s $210M Series D+ round.

Clinical Mental Health Apps had the opposite profile. They produced 20.83% of deals but only 4.14% of capital, which suggests investors will fund clinical AI and app layers, but at discounted check sizes unless they are tied to regulated workflows.

Which geographies matter most for fundraising in the mental health market?

As of June 2026, North America matters most for fundraising in the mental health market by a wide margin. Over the past 12 months, the region captured 22 of 24 deals and $1.373B, equal to 99.47% of disclosed capital.

North America also produced much larger checks than the other regions in the dataset. Its average deal size was $62.43M, and its median deal size was $25M.

Asia-Pacific appeared through Amaha’s $6M round, while Europe appeared through Clearly’s $1.35M round. Both regions were visible, but neither came close to North America’s funding depth.

The geography split shows a market that is globally searchable but not globally capitalized. Publicly disclosed venture-scale clinical mental-health funding remains overwhelmingly concentrated in North America.

For more context on where the market is capitalizing fastest, see our deeper analysis of the mental health market.

Is the mental health opportunity set broad or concentrated in one hub?

As of June 2026, the mental health opportunity set is concentrated in one dominant funding hub. Over the past 12 months, North America represented 91.67% of deals and 99.47% of total capital.

This is stronger than a simple deal-count imbalance. North America’s capital share is higher than its deal share, which means the region produced not only more rounds but also much larger rounds.

Europe and Asia-Pacific both appeared, but their rounds were small. Europe contributed one $1.35M Seed round, and Asia-Pacific contributed one $6M Series A round.

Latin America, the Middle East, and Africa produced no qualifying disclosed equity rounds in the dataset. That absence should not be read as lack of mental-health need; it reflects where public venture funding is currently visible.

Is mental health a market of small experiments or scaled financings?

As of June 2026, the mental health market contains both small experiments and scaled financings, but the dollars skew toward scaled financings. Over the past 12 months, 7 of 24 deals were $50M or larger, while the median round was $25M.

The lower end of the market is still present. Three deals were below $5M, 7 were between $5M and $20M, and 7 were between $20M and $50M.

The upper end carries the funding story. Seven deals were $50M or larger, and 4 were above $100M, which means a relatively small number of rounds defined most of the capital environment.

This size distribution shows that the mental health market is not merely a long tail of small digital health rounds. It is a market where therapeutics, psychiatry platforms, payer-connected therapy providers, and interventional clinics can raise institutional-scale capital.

If you want to stay on top of the latest funding patterns and clinical categories, check out our market report on mental health.

Who are the investors that appear the most in mental health fundraising?

As of June 2026, General Catalyst is the most visible repeat investor in the mental health market. Over the past 12 months, it appeared in 3 disclosed deals: Cartwheel Care, Radial, and Somethings.

Several investors appeared twice. Goldman Sachs Alternatives participated in MapLight Therapeutics and Grow Therapy, while Menlo Ventures appeared in Cartwheel Care and Grow Therapy.

Town Hall Ventures and Khosla Ventures both appeared in Marble Health and Jimini Health. BoxGroup appeared in Cartwheel Care and Radial, showing overlap between youth mental health, interventional psychiatry, and care-delivery infrastructure.

The repeat-investor list is useful, but it has limits. Round announcements usually disclose total deal size, not each investor’s exact contribution, so investor participation should not be read as dollars personally committed.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.